Lunai Bioworks Inc. (Nasdaq: LNAI) formally adopted its new corporate identity on September 30, 2025, marking a strategic transformation from Renovaro Inc. to focus on AI-powered drug discovery and biodefense applications. The rebranding coincides with a 10:1 reverse stock split that reduced outstanding shares from approximately 231.8 million to 23.2 million shares.
The company positions itself at the intersection of artificial intelligence, healthcare, and global security, with a mission to capture biological signals at scale, decode them using AI, and validate them quickly in model systems. "Our new identity reflects both who we are and where we're going," said Dr. Gabe Musso, Chief Scientific Officer of Lunai's wholly owned subsidiary, BioSymetrics Inc. "We're building platforms that not only accelerate therapeutic discovery but also safeguard against emerging biological threats."
AI Platform Development and Neurotoxicity Intelligence
Lunai introduced a proprietary transformer-based platform that embeds neurotoxicity intelligence into generative AI pipelines. This innovation enables safe compound discovery while mitigating dual-use risks in biodefense applications. The platform represents a significant advancement in addressing safety concerns associated with AI-generated therapeutic compounds.
The company's Augusta platform advances precision neurology through AI-integrated therapeutics and biomarker intelligence. CEO David Weinstein emphasized the platform's potential, stating, "With our Augusta platform, Lunai Bioworks is advancing precision neurology through AI-integrated therapeutics and biomarker intelligence. This transformation reflects our commitment to restoring cognitive health and resilience at scale."
Parkinson's Disease Research Initiative
Through BioSymetrics, Lunai advanced a preclinical biomarker discovery initiative in Parkinson's Disease, leveraging phenogrouping and multimodal data to stratify patients and identify novel therapeutic targets. This research program represents a key application of the company's AI-driven approach to neurological disorders.
The Parkinson's biomarker program utilizes advanced data analysis techniques to better understand disease progression and identify potential intervention points. This work aligns with the company's broader mission to restore cognitive health through precision medicine approaches.
NIH Grant Validation and Platform Expansion
BioSymetrics recently secured a multi-year Small Business Technology Transfer (STTR) grant from the National Institutes of Health, providing validation for the company's platform technology. The competitive grant will enable platform expansion and further development of the company's AI-driven drug discovery capabilities.
This federal funding represents significant external validation of Lunai's scientific approach and technological platform. The multi-year nature of the grant provides sustained support for continued research and development activities.
Capital Structure and Strategic Positioning
The reverse stock split enhances capital efficiency and aligns with Nasdaq's minimum bid price requirements, strengthening Lunai's financial profile for long-term growth. The restructuring facilitates strategic partnerships with pharmaceutical, biotechnology, and government agencies.
Lunai Bioworks describes itself as pioneering safe and responsible generative biology, with proprietary neurotoxicity datasets, advanced machine learning capabilities, and a focus on dual-use risk management. The company aims to redefine how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging biological threats.
